AFG
HAE icon

ABLE Financial Group’s Haemonetics HAE Stock Holding History

ABLE Financial Group’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-8,973
Closed -$766K – 182
2024
Q1 		$766K Buy
8,973
+1,722
+24% +$135K 0.3% 60
2023
Q4 		$620K Buy
7,251
+1,606
+28% +$139K 0.27% 69
2023
Q3 		$506K Buy
+5,645
New +$504K 0.25% 75

Other funds holding HAE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ABLE Financial Group's HAE Position: Q2 2024 in Review

ABLE Financial Group sold out of Haemonetics (HAE) in Q2 2024, closing a stake of 8,973 shares — an estimated $766K sold.

ABLE Financial Group first reported a position in HAE in Q3 2023 and held it in 3 quarters. The position peaked at $766K in Q1 2024. 317 funds tracked by Wall St. Rank hold HAE as of Q2 2024.

  • ABLE Financial Group reported no remaining Haemonetics position as of Q2 2024 after selling out during the quarter.
  • ABLE Financial Group sold 8,973 Haemonetics shares in Q2 2024, an estimated $766K.
  • ABLE Financial Group first reported a position in Haemonetics in Q3 2023 and held it in 3 quarters.
  • ABLE Financial Group's Haemonetics position peaked at $766K in Q1 2024.
  • 317 funds tracked by Wall St. Rank held Haemonetics as of Q2 2024.

Based on ABLE Financial Group's 13F filing for Q2 2024, filed 26 Jul 2024.